MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Cancer Research

• Publication date

  2017-07-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-17-0980PMID 28720667
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2017

  2017cited by this paper
• NF1‐mutated melanoma tumors harbor distinct clinical and biological characteristics

  2017cited by this paper
• Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma

  2017cited by this paper
• TERT promoter mutations associate with fast‐growing melanoma

  2016cited by this paper
• Cancer statistics in China, 2015

  2016cited by this paper
• Therapeutic implications of melanoma heterogeneity

  2016cited by this paper
• Braf V600E mutation in melanoma: translational current scenario

  2016cited by this paper
• Genetics of melanoma progression: the rise and fall of cell senescence

  2016cited by this paper
• Mucosal malignant melanoma – a clinical, oncological, pathological and genetic survey

  2016cited by this paper
• From melanocytes to melanomas

  2016cited by this paper
• Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.

  2015cited by this paper
• The Genetic Evolution of Melanoma from Precursor Lesions.

  2015cited by this paper
• Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma.

  2015cited by this paper
• TERT promoter mutation is absent in oral mucosal melanoma.

  2015cited by this paper
• Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas

  2015cited by this paper
• A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor

  2015cited by this paper
• Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness

  2015cited by this paper
• Genomic Classification of Cutaneous Melanoma.

  2015cited by this paper
• TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.

  2014cited by this paper
• Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma

  2014cited by this paper
• TERT promoter mutation is uncommon in acral lentiginous melanoma

  2014cited by this paper
• TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation.

  2014cited by this paper
• Absence of TERT promoter mutations in primary melanocytic tumours of the central nervous system

  2014cited by this paper
• Highly Recurrent TERT Promoter Mutations in Human Melanoma

  2013cited by this paper
• BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage

  2013cited by this paper
• Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

  2013cited by this paper
• Frequency of TERT promoter mutations in human cancers

  2013influential reference
• TERT Promoter Mutations in Familial and Sporadic Melanoma

  2013cited by this paper
• Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.

  2012cited by this paper
• Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

  2012cited by this paper
• NRAS mutation status is an independent prognostic factor in metastatic melanoma

  2012cited by this paper
• A landscape of driver mutations in melanoma.

  2012cited by this paper
• Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma

  2011cited by this paper
• Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases

  2011cited by this paper
• Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma

  2010cited by this paper
• Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005.

  2009cited by this paper
• Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma.

  2009cited by this paper
• Neurofibromin as a regulator of melanocyte development and differentiation

  2008cited by this paper
• Distinct sets of genetic alterations in melanoma.

  2005cited by this paper
• Incidence of noncutaneous melanomas in the U.S.

  2005cited by this paper
• BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.

  2003cited by this paper
• NF1 tumor suppressor gene function: narrowing the GAP.

  2001cited by this paper
• Cancer statistics

  1989cited by this paper
• Highly Recurrent TERT Promoter Mutations in Human Melanoma

  year unknowncited by this paper
• Journal of Translational Medicine Clinical Significance of Braf Mutations in Metastatic Melanoma Metastatic Melanomabraf Mutationclinical Significance

  year unknowncited by this paper

• Ancillary Molecular Tests for the Diagnosis of Melanocytic Tumors

  2026cites this paper
• Melanoma: Pathogenesis and Targeted Therapy

  2026cites this paper
• Socioeconomic status correlates with clinical outcomes in patients with acral melanoma

  2025cites this paper
• Genomic characterization reveals distinct mutational landscape of acral melanoma in East Asian.

  2025cites this paper
• Routine sequencing of BRAF exon 15 improves therapeutic stratification for metastatic melanoma.

  2025cites this paper
• Immune checkpoint inhibitors in melanoma: mechanisms, immune cell interactions, and the tumour microenvironment

  2025influential citation
• C‐Reactive Protein Kinetics as Prognostic Biomarkers in Stage IV‐Melanoma Treated With Immune Checkpoint Inhibitors in the Japanese Population: A Single‐Center, Retrospective Cohort Study

  2025cites this paper
• Association of the BRAFV600E mutation with morphology and heterogeneity in melanoma.

  2025cites this paper
• Targeted therapies induced depigmentation: a review

  2025cites this paper
• Confronting Melanoma Radioresistance: Mechanisms and Therapeutic Strategies

  2025cites this paper
• Recent Advances in Molecular Research and Treatment for Melanoma in Asian Populations

  2025cites this paper
• Therapeutic Approaches to Mucosal Melanoma.

  2025cites this paper
• Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma

  2025cites this paper
• Combination Immunotherapy for Mucosal Melanoma: Molecular Mechanism, Research Status, and Future Directions

  2025cites this paper
• DNA Methylation Array Analysis Identifies Biological Subgroups of Cutaneous Melanoma and Reveals Extensive Differences with Benign Melanocytic Nevi

  2025cites this paper
• Addition of anti‐PD‐1 immunotherapy to BRAF inhibitor‐based targeted therapy improves real‐world survival and delays brain metastases in patients with BRAFV600‐mutant advanced melanoma: a multicenter cohort study

  2025cites this paper
• Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations

  2024cites this paper
• Primary Malignant Melanoma of the Larynx: Case Report and Literature Review

  2024influential citation
• Ancestry and somatic profile predict acral melanoma origin and prognosis

  2024cites this paper
• Mucosal Melanoma: Review from a Pathologist Point of View.

  2024cites this paper
• Predominance of hyperprogression in mucosal melanoma during anti-PD-1 monotherapy treatment

  2024cites this paper
• Comprehensive insights on genetic alterations and immunotherapy prognosis in Chinese melanoma patients

  2024cites this paper
• Efficacy of axitinib in a US cohort of patients with programmed cell death protein 1–resistant mucosal melanoma

  2024cites this paper
• Cutaneous melanocytic tumor with CRTC1::TRIM11 fusion: a case report

  2024cites this paper
• CRISPR-Cas9 screening identified novel subtypes of cutaneous melanoma based on essential cancer genes

  2024cites this paper
• Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study

  2023cites this paper
• Immunotherapy for mucosal melanoma

  2023cites this paper
• Challenges and opportunities in rare cancer research in China

  2023influential citation
• Prognostic value of genetic aberrations and tumor immune microenvironment in primary acral melanoma

  2023cites this paper
• Comparative analysis of adjuvant therapy for stage III BRAF‐mut melanoma: A real‐world retrospective study from single center in China

  2023cites this paper
• Treatment of Acral and Mucosal Melanoma: Current and Emerging Targeted Therapies.

  2023cites this paper
• Phase II Clinical Trial of Neoadjuvant anti-PD-1 (Toripalimab) Combined with Axitinib in Resectable Mucosal Melanoma.

  2023cites this paper
• A real‐world study of adjuvant anti‐PD ‐1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations

  2023cites this paper
• Phase Ib study of anlotinib in combination with anti‐PD‐L1 antibody (TQB2450) in patients with advanced acral melanoma

  2023cites this paper
• Clinicopathological Features and Prognosis of Melanoma in Northeast China: a region-based cohort study of 229 consecutive cases.

  2023cites this paper
• [Clinicopathological features and prognosis of anorectal melanoma: A report of 68 cases].

  2023cites this paper
• Immune checkpoint inhibitor‐based therapy for advanced acral and mucosal melanoma

  2022cites this paper
• Identification of potential inhibitors of cutaneous Melanoma and Non-Melanoma skin cancer cells through in-vitro and in-silico screening of a small library of Phenolic compounds

  2022cites this paper
• Molecular Profile of Cutaneous Melanoma

  2022cites this paper
• Pan-cancer prognostic genetic mutations and clinicopathological factors associated with survival outcomes: a systematic review

  2022cites this paper
• Evolving Treatment Approaches to Mucosal Melanoma

  2022cites this paper
• FMRP ligand circZNF609 destabilizes RAC1 mRNA to reduce metastasis in acral melanoma and cutaneous melanoma

  2022cites this paper
• Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.

  2022cites this paper
• Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts

  2022influential citation
• Molecular testing in melanoma for the surgical pathologist.

  2022cites this paper
• Analysis of Cost-Effectiveness of Trametinib Plus Dabrafenib as First-Line Therapy for Metastatic BRAF V600-Mutated Melanoma in China

  2021cites this paper
• Biology of Melanoma.

  2021cites this paper
• Incorporating VEGF Blockade Into a Shifting Treatment Paradigm for Mucosal Melanoma.

  2021cites this paper
• Real-world analysis of clinicopathological characteristics, survival rates, and prognostic factors in patients with melanoma brain metastases in China

  2021cites this paper
• Distribution and clinical role of KIT gene mutations in melanoma according to subtype. A study on 492 Spanish patients

  2021cites this paper
• TERT promoter mutations and melanoma survival: a comprehensive literature review and meta-analysis.

  2021cites this paper
• Survival Benefits of Anti-PD-1 Therapy in Combination With Radiotherapy in Chinese Melanoma Patients With Brain Metastasis

  2021influential citation
• BRAF, C-KIT, and NRAS mutations correlated with different clinicopathological features: an analysis of 691 melanoma patients from a single center

  2021cites this paper
• Clinical significance of CCNE1 copy number gain in acral melanoma patients

  2021cites this paper
• Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies

  2021cites this paper
• Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions

  2021cites this paper
• Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials

  2021cites this paper
• [The significance of C-KIT gene mutations in the diagnosis and prognosis of malignant tumors].

  2021cites this paper
• Clinical Application of TERT Promoter Mutations in Urothelial Carcinoma

  2021cites this paper
• Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal Melanomas

  2021cites this paper
• TERT Promoter Mutational Status in the Management of Cutaneous Melanoma: Comparison with Sentinel Lymph Node Biopsy

  2021cites this paper
• Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)

  2021cites this paper
• Molecular testing for melanocytic tumors: a practical update

  2021cites this paper
• Gene mutations and clinical prognosis of mucosal melanoma in different locations of head and neck

  2021cites this paper
• The Mutational Landscape of Mucosal Melanoma.

  2020cites this paper
• Gene Mutation Characteristics and Clinical Prognosis of Head and Neck Mucosal Melanoma

  2020cites this paper
• The Association Between Breast Cancer and Blood-Based Methylation of S100P and HYAL2 in the Chinese Population

  2020cites this paper
• Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives

  2020cites this paper
• Genetic alterations in primary melanoma in Taiwan

  2020cites this paper
• Mutational profiling of melanomas in patients from the southeast coast of China

  2020cites this paper
• TERT drives fibroblasts reprogramming to promote the invasion of head and neck squamous cell carcinoma via transferring of exosomal MET protein

  2020cites this paper
• TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma

  2020cites this paper
• Frequency of CDK2 , CCNE1 Copy Number Variation in Acral Melanoma and Implications for CDK Inhibitor in Targeted Therapy

  2020cites this paper
• PD-1 Blockade in Japanese Patients with Acral Lentiginous Melanoma.

  2020cites this paper
• PD-1 Blockade in Chinese versus Western Patients with Melanoma

  2020cites this paper
• A Functional Synonymous Variant in PDGFRA Is Associated with Better Survival in Acral Melanoma

  2020cites this paper
• TERT and TERT promoter in melanocytic neoplasms: Current concepts in pathogenesis, diagnosis, and prognosis

  2020cites this paper
• Characterizations of Gene Alterations in Melanoma Patients from Chinese Population

  2020cites this paper
• BIANCA DEL BIANCO SAHM MODULAÇÃO DO FATOR DE TRANSCRIÇÃO TBX2 COMO NOVA ESTRATÉGIA ANTICÂNCER: ESTUDO BASEADO NA ATIVIDADE BIOLÓGICA DE CROMOMICINA A5 EM CÉLULAS DE MELANOMA

  2020cites this paper
• Potential Mutations in Uveal Melanoma Identified Using Targeted Next-Generation Sequencing

  2019cites this paper
• Prognostic role of NRAS isoforms in Chinese melanoma patients

  2019cites this paper
• Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis

  2019cites this paper
• ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab

  2019cites this paper
• Identification of prognostic biomarkers for malignant melanoma using microarray datasets

  2019cites this paper
• Prevalence of NRAS Mutation, PD‐L1 Expression and Amplification, and Overall Survival Analysis in 36 Primary Vaginal Melanomas

  2019cites this paper
• Immunohistochemistry as a Genetic Surrogate in Dermatopathology: Pearls and Pitfalls

  2019cites this paper
• Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma

  2019cites this paper
• miR-342-3p suppresses cell migration and invasion in preeclampsia by targeting platelet-derived growth factor receptor α

  2019cites this paper
• Effect of YAP on an Immortalized Periodontal Ligament Stem Cell Line

  2019cites this paper
• Prognostic significance of human telomerase reverse transcriptase promoter region mutations C228T and C250T for overall survival in spinal chordomas

  2019cites this paper
• The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma

  2019cites this paper
• The clinical significance of KIT mutations in melanoma: a meta-analysis

  2018cites this paper
• Acral Lentiginous Melanoma

  2018cites this paper
• Molecular Epidemiology of Melanoma

  2018cites this paper
• Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches

  2018cites this paper
• Establishment and characterization of melanoma patient-derived xenograft models for preclinical evaluation of novel therapeutics

  2018cites this paper
• Telomere Maintenance Mechanisms in Cancer

  2018cites this paper
• The association between dermoscopic features and BRAF mutational status in cutaneous melanoma: Significance of the blue‐white veil

  2018cites this paper